Estimating cancer risk from ^99mTc pyrophosphate imaging for transthyretin cardiac amyloidosis.

ABSTRACT:

Background

Increasing recognition that transthyretin cardiac amyloidosis (ATTR-CA) is much more common than previously appreciated and the emergence of novel disease-modifying therapeutic agents have led to a paradigm shift in which ATTR-CA screening is considered in high-risk populations, such as patients with heart failure with preserved ejection fraction (HFpEF) or aortic stenosis. Radiation risk from ^99mTc-pyrophosphate (^99mTc-PYP) scintigraphy, a test with very high sensitivity and specificity for ATTR-CA, has not been previously determined.

Methods and results

Radiation doses to individual organs from ^99mTc-PYP were estimated using models developed by the Medical Internal Radiation Dose Committee and the International Commission on Radi

SUBMITTER: Einstein AJ 

PROVIDER: S-EPMC6269210 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature